Article

Bevacizumab appears safe for neovascular AMD in short term

The short-term clinical experience with intravitreal bevacizumab (Avastin, Genentech) supports growing perception that treatment is safe and effective for neovascular age-related macular degeneration.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Study finds low incidence of microbial keratitis with overnight ortho-k lenses
November 25th 2024

Study finds low incidence of microbial keratitis with overnight ortho-k lenses

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

OCTA reveals retinal vascular damage in patients diagnosed with renal hypertension, offers early diagnostic insights
November 25th 2024

OCTA reveals retinal vascular damage in patients diagnosed with renal hypertension, offers early diagnostic insights

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Ocular pain in Tibetan Plateau residents: Key findings on dry eye disease during COVID-19
November 24th 2024

Ocular pain in Tibetan Plateau residents: Key findings on dry eye disease during COVID-19

NHS introduces OCT scans nationwide to improve diabetic eye care
November 24th 2024

NHS introduces OCT scans nationwide to improve diabetic eye care

© 2024 MJH Life Sciences

All rights reserved.